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Abstract 
Background: Nasal‑type extranodal natural killer/T‑cell lymphoma (ENKTCL) originates primarily in the nasal cavity or 
extra‑nasal sites within the upper aerodigestive tract. However, it is unclear whether the primary site can serve as an 
independent prognostic factor or whether the varying clinical outcomes observed with different primary sites can be 
attributed merely to their propensities of regional lymph node involvement. The aim of this study was to investigate 
the prognostic implications of the primary site and regional lymph node involvement in patients with early‑stage 
nasal‑type ENKTCL.
Methods: To develop a nomogram, we reviewed the clinical data of 215 consecutively diagnosed patients with 
early‑stage nasal‑type ENKTCL who were treated in Sun Yat‑sen University Cancer Center with chemotherapy and 
radiotherapy between 2000 and 2011. The predictive accuracy and discriminative ability of the nomogram were 
determined using a concordance index (C‑index) and calibration curve.
Results: The 5‑year overall survival (OS) and progression‑free survival (PFS) rates of patients with nasal ENKTCL were 
higher than those of patients with extra‑nasal ENKTCL (OS: 68.2% vs. 46.0%, P = 0.030; PFS: 53.4% vs. 26.6%, P = 0.010). 
The 5‑year OS and PFS rates of patients with Ann Arbor stage IE ENKTCL were higher than those of patients with 
Ann Arbor stage IIE ENKTCL (OS: 66.3% vs. 59.2%, P = 0.003; PFS: 51.4% vs. 40.3%, P = 0.009). Multivariate analysis 
showed that age >60 years, ECOG performance status score ≥2, elevated lactate dehydrogenase (LDH) level, extra‑
nasal primary site, and regional lymph node involvement were significantly associated with lower 5‑year OS rate; 
age >60 years, elevated LDH level, extra‑nasal primary site, and regional lymph node involvement were significantly 
associated with lower 5‑year PFS rate. The nomogram included the primary site and regional lymph node involve‑
ment based on multivariate analysis. The calibration curve showed good agreement between the predicted and 
actual 5‑year OS and PFS rates, and the C‑indexes of the nomogram for the OS and PFS rates were 0.697 and 0.634, 
respectively.
Conclusions: The primary site and regional lymph node involvement are independent prognostic factors for early‑
stage ENKTCL treated with chemotherapy followed by definitive radiotherapy.
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Background
According to the World Health Organization (WHO) 
classification, nasal-type extranodal natural killer (NK)/
T-cell lymphoma (ENKTCL) is a distinct histopathologic 
type of non-Hodgkin lymphoma [1]. Most ENKTCL orig-
inates in the upper aerodigestive tract (UADT), which 
includes the nasal cavity, nasopharynx, paranasal sinuses, 
tonsils, hypopharynx, and larynx [2–4]. Most published 
studies reported the use of anthracycline-based chemo-
therapy; however, unsatisfactory results were obtained 
[5]. Therefore, L-asparaginase-based chemotherapy regi-
mens are currently being investigated [6–10]. Although 
the optimal treatment remains unknown, definitive 
radiotherapy used upfront or after short-course chemo-
therapy is considered the standard treatment for early-
stage ENKTCL [11–15]. Previous studies found that 
regional lymph node involvement is more common in 
patients with ENKTCL that originates in the Waldeyer’s 
ring or has involvement in the Waldeyer’s ring, and this 
variance can contribute to differences in long-term sur-
vival [16–19]. These studies considered the primary site 
of the disease to be a significant prognostic factor. How-
ever, it is unclear whether the primary site can serve as an 
independent prognostic factor or whether it merely acts 
through its interaction with regional lymph node involve-
ment or disease stage.
 Nomogram is a graphical statistical prediction model 
that provides a clearly decipherable prediction and can 
be used to determine the relationship between multiple 
prognostic factors [20–22]. The performance (discrimi-
nation and calibration) of a nomogram has been rigor-
ously assessed, although no study to date has reported 
the use of nomogram prediction for patients with early-
stage UADT-ENKTCL. Hence, the goal of our study was 
to use a nomogram to determine whether the primary 
site and regional lymph node involvement are independ-
ent prognostic factors for this lymphoma.
Patients and methods
Patient selection
This study included 215 patients diagnosed with Ann 
Arbor stages IE–IIE UADT-ENKTCL between Janu-
ary 2000 and December 2011 at Sun Yat-sen University 
Cancer Center. The diagnostic criteria were based on 
the WHO classification of tumors of hematopoietic and 
lymphoid tissues [1]. Based on a patient’s primary symp-
toms and if the majority of the lymphoma bulk presented 
in the nasal cavity, with or without extension to adjacent 
structures, the disease was considered primary nasal 
cavity ENKTCL (nasal ENKTCL); if the majority of the 
lymphoma bulk presented in extra-nasal sites, the disease 
was considered extra-nasal ENKTCL. Local tumor inva-
siveness (LTI) was defined as extension of the primary 
site, bone invasion, or perforation or invasion of the skin 
[23]. The diseases of all patients were staged according 
to the Ann Arbor staging system. The clinical evaluation 
of patients included a history and physical examination, 
complete blood count, liver and renal function tests, 
serum lactate dehydrogenase (LDH) level detection, 
chest radiograph, computed tomography of the chest and 
abdomen/pelvis, bone marrow aspiration and/or biopsy, 
and computed tomography and/or magnetic resonance 
imaging of the head and neck.
Treatment
All patients received radiotherapy: 4 patients received 
radiotherapy alone, and 211 patients received a combi-
nation of radiotherapy and chemotherapy (202 received 
chemotherapy followed by radiotherapy, and 9 received 
radiotherapy followed by chemotherapy). The chemo-
therapy regimen was mostly anthracycline-based, 
including a cyclophosphamide, doxorubicin, vincris-
tine, and prednisolone (CHOP) or CHOP-like regimen 
in 175 patients and an L-asparaginase-based regimen 
in 31 patients; 5 patients received other chemotherapy 
regimens. The median number of chemotherapy cycles 
before radiotherapy was 3 cycles (range, 1–9 cycles). 
Radiotherapy was administered with a 6-MV or 8-MV 
linear accelerator. The median dose was 55  Gy (36–
70  Gy) with conventional fractionation; 181 patients 
(84.2%) received radiotherapy with a dose range of 
46–70 Gy (median, 56 Gy).
Construction of the nomogram
The variables for the nomogram were selected based on 
variables that have been previously shown to be associ-
ated with survival. These variables included age, eastern 
cooperative oncology group (ECOG) performance sta-
tus (PS), LTI, “B” symptoms, LDH levels, regional lymph 
node involvement, and the primary site of disease. A 
multivariable Cox proportional hazards model was used 
to estimate the 5-year overall survival (OS) and progres-
sion-free survival (PFS) rates for each variable. Discrimi-
nation and calibration powers were examined using a 
concordance index (C-index) and a calibration curve.
Statistical analysis
OS was measured from the start of the initial treatment 
until the time of death from any cause or until the last 
follow-up. PFS was measured from the start of the ini-
tial treatment until the first loco-regional or distant 
progression, relapse, last follow-up, or death. A survival 
curve was constructed using the Kaplan–Meier method, 
and the groups were compared using the log-rank test. 
A multivariable Cox proportional hazards model was 
used to confirm independent prognostic factors, and 
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the nomogram was constructed based on the Cox model 
parameters. The selection of the final model was deter-
mined by a backward step-down selection process. The 
C-index was estimated by analyzing the area under the 
curve of the receiver operating characteristic (ROC) 
curve to calculate an unbiased measure of the validity of 
the model. Statistical analyses were performed using IBM 
SPSS Statistics software, version 20.0 (IBM, Chicago, 




In all 215 patients included in this study, the ratio of 
men to women was 1.9:1, and only 27 patients (12.6%) 
were 60 years of age or older (range, 9–80 years; median, 
42  years). Of the 215 patients, 67 (31.2%) had regional 
node involvement (or Ann Arbor stage IIE disease), 
and 87 (40.5%) presented with systemic symptoms; 207 
(96.3%) had an ambulatory ECOG PS of 0–1, and 43 
(20.0%) had an elevated LDH level; 126 (58.6%) presented 
with LTI. Similar clinical characteristics were observed in 
patients whose primary tumor was located in the nasal 
cavity (nasal ENKTCL) and in extra-nasal sites (extra-
nasal ENKTCL). The baseline characteristics of the 
cohort are detailed in Table 1.
Survival and univariate analysis
After a median follow-up of 47.7 months, 68 patients had 
died. The 5-year OS and PFS rates were 63.6% and 47.9%, 
respectively (Fig.  1). According to the univariate analy-
sis results, the following variables were associated with 
the OS rate: age (>60 vs.  ≤60  years, 38.9% vs. 66.7%, 
P = 0.001), performance status (ECOG score ≥2 vs. <2, 
25.0% vs. 65.4%, P = 0.008), LDH level (increased level vs. 
normal, 48.7% vs. 67.3%, P = 0.002), extra-nasal primary 
site of lymphoma (yes vs. no, 46.0% vs. 68.2%, P = 0.030, 
Fig.  2a), and regional lymph node involvement (yes vs. 
no, 59.2% vs. 66.3%, P  =  0.003, Fig.  2b). The following 
variables were associated with the PFS rate: LDH level 
(increased level vs. normal, 35.6% vs. 51.2%, P = 0.006), 
extra-nasal primary site of lymphoma (yes vs. no, 26.6% 
vs. 53.4%, P =  0.010, Fig.  2c), and regional lymph node 
involvement (yes vs. no, 40.3% vs. 51.4%, P  =  0.009, 
Fig. 2d). 
For Ann Arbor stage IE patients, the 5-year OS rate 
was 71.5% for those with nasal ENKTCL and 40.2% for 
those with extra-nasal ENKTCL (P  =  0.019, Fig.  3a), 
with a trend toward a higher PFS rate (56.4% vs. 30.0%, 
P  =  0.071, Fig.  3b). For Ann Arbor stage IIE patients, 
the 5-year OS rate was 61.4% for those with nasal ENK-
TCL and 53.8% for those with extra-nasal ENKTCL 
(P  =  0.683, Fig.  3c); the 5-year PFS rate was 46.0% for 
patients with nasal ENKTCL and 25.0% for patients with 
extra-nasal ENKTCL (P = 0.142, Fig. 3d).
Prognostic nomogram for OS and PFS
A multivariate analysis was conducted using Cox pro-
portional hazards regression, and this Cox model was 
the basis for the nomogram. The multivariate analy-
sis results for the 215 patients with complete data 
are presented in Table  2. Age  >60  years (hazard ratio 
[HR] = 3.365, P < 0.001), ECOG score ≥2 (HR = 2.439, 
P = 0.040), elevated LDH level (HR = 2.422, P = 0.001), 
extra-nasal primary site (HR  =  1.860, P  =  0.022), and 
regional lymph node involvement (HR, 1.796; P = 0.024) 
were significantly associated with a lower 5-year OS 
rate. Age  >60  years (HR  =  1.720, P  =  0.057), elevated 
LDH level (HR = 1.942, P = 0.005), extra-nasal primary 
site (HR =  1.857, P =  0.007), and regional lymph node 
involvement (HR =  1.716, P =  0.014) were significantly 
associated with a lower 5-year PFS rate.
Table 1 Clinicopathologic characteristics of  patients 
with early-stage UADT-ENKTCL
All values are presented as the number of patients followed by the percentages 
in the parentheses
UADT-ENKTCL upper aerodigestive tract-extranodal natural killer/T-cell 
lymphoma, LDH lactate dehydrogenase, LTI local tumor invasiveness, ECOG 
eastern cooperative oncology group








 Men 141 (65.6) 113 (66.5) 28 (62.2)
 Women 74 (34.4) 57 (33.5) 17 (37.8)
Age (years) 0.404
 ≤60 188 (87.4) 147 (86.5) 41 (91.1)
 >60 27 (12.6) 23 (13.5) 4 (8.9)
Regional lymph node involvement 0.150
 Yes 67 (31.2) 49 (28.8) 18 (40.0)
 No 148 (68.8) 121 (71.2) 27 (60.0)
“B” symptoms 0.048
 Yes 87 (40.5) 63 (37.1) 24 (53.3)
 No 128 (59.5) 107 (62.9) 21 (46.7)
Elevated LDH 0.675
 Yes 43 (20.0) 35 (20.6) 8 (17.8)
 No 172 (80.0) 135 (79.4) 37 (82.2)
LTI 0.137
 Yes 126 (58.6) 104 (61.2) 22 (48.9)
 No 89 (41.4) 66 (38.8) 23 (51.1)
ECOG score 0.773
 0–1 207 (96.3) 164 (96.5) 43 (95.6)
 ≥2 8 (3.7) 6 (3.5) 2 (4.4)
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The prognostic nomogram that includes all significant 
independent factors for the 5-year OS and PFS rates is 
presented in Fig. 4a and b. Based on this nomogram, an 
individual patient’s value for each variable was scored by 
locating the corresponding position on the variable scale 
and drawing a vertical line to determine the correspond-
ing points. The total points were then tallied, and a verti-
cal line was drawn through the survival scales to calculate 
a 5-year survival rate. The calibration plot for the 5-year 
survival rate showed an optimal agreement between the 
prediction obtained with the nomogram and the actual 
observation (Fig.  5a, b). The C-indexes for OS and PFS 
prediction by the nomogram were 0.697 and 0.634, 
respectively (Fig. 5c, d).
Discussion
Our results confirm that the primary site and regional 
lymph node involvement were both significant prognos-
tic factors in patients with early-stage UADT-ENKTCL 
who received definitive radiotherapy that was admin-
istered mainly after chemotherapy. Patients with Ann 
Arbor stage IE disease or nasal ENKTCL had a favorable 
prognosis, with the 5-year OS and PFS rates of approxi-
mately 70%–50%, respectively.
Fig. 1 Overall survival (OS) and progression‑free survival (PFS) of 215 
patients with early‑stage nasal‑type extranodal natural killer/T‑cell 
lymphoma (ENKTCL)
Fig. 2 Kaplan‑Meier OS and PFS curves for patients with ENKTCL categorized by primary site and regional lymph node involvement. a OS curves for 
patients with nasal and extra‑nasal disease; b OS curves for patients with Ann Arbor stage IIE or IE disease (i.e., with or without regional lymph node 
involvement); c PFS curves for patients with nasal and extra‑nasal disease; d PFS curves for patients with Ann Arbor stage IE or IIE disease
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Patients with ENKTCL at different sites have different 
clinical presentations. The UADT is the most common 
involved site of NK/T-cell lymphoma. Most patients with 
UADT-ENKTCL (60%–80%) present with early-stage 
disease, although only a small proportion of patients 
(10%–40%) show regional lymph node involvement 
(Ann Arbor stage IIE) [2, 22–25]. However, compared 
with patients with nasal ENKTCL, patients with extra-
nasal UADT-ENKTCL are more likely to present with 
regional lymph node involvement, and the involvement 
of regional lymph nodes has been shown to be associ-
ated with poor outcomes [17–19, 24]. Patients with 
Fig. 3 Survival curves for patients with nasal and extra‑nasal ENKTCL at Ann Arbor stage IE and IIE. a OS for patients with nasal and extra‑nasal 
disease at Ann Arbor stage IE; b PFS for patients with nasal and extra‑nasal disease at Ann Arbor stage IE; c OS for patients with nasal and extra‑nasal 
disease at Ann Arbor stage IIE; d PFS for patients with nasal and extra‑nasal disease at Ann Arbor stage IIE
Table 2 Multivariate analysis of 215 patients with early-stage UADT-ENKTCL
HR hazard ratio, CI confidence interval, UADT-ENKTCL upper aerodigestive tract-extranodal natural killer/T-cell lymphoma, LDH lactate dehydrogenase, LTI local tumor 
invasiveness, ECOG eastern cooperative oncology group
Variable Overall survival Progression-free survival
HR 95% CI P HR 95% CI P
Primary site (extra‑nasal vs. nasal) 1.860 1.092–3.169 0.022 1.857 1.182–2.916 0.007
Regional lymph node involvement (yes vs. no) 1.796 1.080–2.986 0.024 1.716 1.116–2.637 0.014
Age (>60 vs. ≤60 years) 3.365 1.867–6.066 <0.001 1.720 0.984–3.006 0.057
Elevated LDH level (yes vs. no) 2.422 1.419–4.132 0.001 1.942 1.218–3.093 0.005
ECOG score (≥2 vs. 0–1) 2.439 1.410–5.690 0.040 – – –
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extra-nasal UADT-ENKTCL also have higher LDH lev-
els, more bulky disease, and a worse performance status. 
All these adverse clinical features may contribute to their 
poor survival [18]. Previous studies that included patients 
with advanced-stage (stages IIIE–IVE) diseases and some 
patients who received only chemotherapy have suggested 
that, based on univariate analysis, the primary site of the 
tumor may be a prognostic factor [16, 17, 19, 25]. There-
fore, we initially confirmed the primary site as an inde-
pendent prognostic factor for patients with early-stage 
(stages I–II) UADT-ENKTCL using univariate and multi-
variate analyses. Age, performance status, LDH level, and 
local regional lymph node involvement were also con-
firmed as independent prognostic factors.
For studies with time-to-event data, a Cox proportional 
hazards model has been used as a standard method. 
However, the performance (discrimination and calibra-
tion) of this model has generally not been rigorously 
assessed, and it is not an ideal tool for the prediction of 
an individual patient’s outcome. The nomogram used in 
our study, which performed well in predicting long-term 
survival, clearly suggested primary site and locoregional 
lymph node involvement as independent prognostic fac-
tors for both OS and PFS in patients with early-stage 
(stages I–II) UADT-ENKTCL; this prediction was sup-
ported by validation (the C-indexes for OS and PFS were 
0.697 and  0.634, respectively) and a calibration curve. 
Furthermore, the nomogram is a practical, predictive 
Fig. 4 A nomogram for patients with early‑stage upper aerodigestive tract natural killer/T‑cell lymphoma. To use the nomogram, an individual 
patient’s value is located on each variable axis, and a line is drawn upward to determine the number of points received for each variable value. The 
sum of these numbers is located on the total points axis, and a line is drawn downward to the survival axes to determine the likelihood of 5‑year OS 
(a) and PFS (b) rates. Site primary site of the lymphoma, LDH pretreatment level of serum lactate dehydrogenase, ECOG eastern cooperative oncol‑
ogy group, LN regional lymph node
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tool for determining prognosis, owing to the fact that the 
clinical variables used in the model are readily available 
to any physician.
In recent years, radiotherapy has been considered 
the most effective treatment for early-stage ENKTCL, 
resulting in a 50%–90% long-term survival rate [26–28]. 
However, radiotherapy may result in different outcomes 
depending on whether it is used upfront or whether it 
is delayed. Li and colleagues [17, 19] reported the clini-
cal features and outcomes of 95 patients with early-stage 
Waldeyer’s ring ENKTCL (WR-ENKTCL) compared 
with those of 145 patients with early-stage nasal ENK-
TCL; their results indicated that patients with Ann Arbor 
stage IIE WR-ENKTCL had higher 5-year OS and PFS 
rates than patients with nasal ENKTCL at the same stage. 
In contrast, we found that nasal ENKTCL patients had 
higher 5-year OS and PFS rates than extra-nasal ENK-
TCL patients, and patients with Ann Arbor stage IE 
nasal ENKTCL had a higher 5-year OS rate than patients 
with extra-nasal ENKTCL, although the 5-year OS rate 
Fig. 5 Internal validation of the nomogram used to predict OS and PFS in patients with upper aerodigestive tract nasal‑type extranodal natural 
killer/T‑cell lymphoma. Discrimination and Calibration: Calibration plot for predicting 5‑year OS rate (a) and 5‑year PFS rate (b). The areas under the 
receiver operating characteristic curve are 0.697 for 5‑year OS rate (c) and 0.634 for 5‑year PFS rate (d). The nomogram‑predicted survival is plotted 
on the X axis; the actual survival is plotted on the Y axis. AUC area under the curve
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between the two groups was similar for patients with Ann 
Arbor stage IIE disease. These differences may be related 
to the initial treatment. In our study, most patients (94%) 
received chemotherapy first, whereas in Li and colleagues’ 
study approximately 60% of patients received radio-
therapy as their first treatment [19]. For patients in our 
study, the 5-year OS and PFS rates were 63.6% and 47.9%, 
respectively, which were lower than the rates in Li and 
colleagues’ study [19]. Because patients with extra-nasal 
ENKTCL are more likely to have Ann Arbor stage IIE 
disease, a possible explanation for this result may be 
that delayed radiotherapy leads to inferior tumor control 
with ineffective initial chemotherapy, and this tendency 
may be more obvious in patients with extra-nasal ENK-
TCL because of the propensity for lymph node metasta-
sis. Thus, we conclude that when patients receive initial 
chemotherapy followed by radiotherapy, patients with 
extra-nasal ENKTCL have lower long-term survival rate 
compared with patients with nasal ENKTCL.
The main limitations of our study were its retrospec-
tive nature and its small sample size because of the lower 
incidence of this tumor in South China. Some potential 
prognostic biomarkers reported in recent years, such as 
Ki-67 scores and circulating Epstein-Barr virus DNA, 
were not included as variables in the nomogram because 
many biological or molecular markers are not widely 
available to physicians during early-phase diagnosis and 
treatment. Furthermore, because ENKTCL that origi-
nates at sites outside of the UADT (e.g., the skin and 
gastrointestinal wall) is rare, patients with these disease 
characteristics were not included in our study.
In conclusion, as demonstrated by a nomogram in our 
group of 215 patients, primary site and regional lymph 
node involvement have clear independent prognostic 
values in early-stage UADT-ENKTCL. In this group of 
patients, those with early-stage nasal ENKTCL may sur-
vive longer than those with extra-nasal ENKTCL at the 
same stage, even though most patients were initially 
treated with chemotherapy followed by definitive radio-
therapy. It is still unclear whether radiotherapy that was 
initially provided and a more effective chemotherapy reg-
imen could alter this prognostic pattern.
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